BOSTON–(BUSINESS WIRE)–PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory High-Risk Myelodysplastic Syndromes & Acute Myeloid Leukemia (AML) at ESMO 2026

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.